4//SEC Filing
Ahrens Brenton Karl 4
Accession 0001209191-18-034204
CIK 0001659323other
Filed
May 29, 8:00 PM ET
Accepted
May 30, 5:26 PM ET
Size
18.5 KB
Accession
0001209191-18-034204
Insider Transaction Report
Form 4
Ahrens Brenton Karl
Director
Transactions
- Conversion
Ordinary Shares
2018-05-30+721,408→ 721,408 total(indirect: By Canaan X, L.P.) - Conversion
Ordinary Shares
2018-05-30+275,446→ 996,854 total(indirect: By Canaan X, L.P.) - Conversion
Series A Preferred Shares
2018-05-30−721,408→ 0 total(indirect: By Canaan X, L.P.)→ Ordinary Shares (721,408 underlying) - Purchase
Ordinary Shares
2018-05-30$13.00/sh+506,656$6,586,528→ 1,733,170 total(indirect: By Canaan X, L.P.) - Conversion
Series B-1 Preferred Shares
2018-05-30−275,446→ 0 total(indirect: By Canaan X, L.P.)→ Ordinary Shares (275,446 underlying) - Conversion
Ordinary Shares
2018-05-30+229,660→ 1,226,514 total(indirect: By Canaan X, L.P.) - Conversion
Series B-2 Preferred Shares
2018-05-30−229,660→ 0 total(indirect: By Canaan X, L.P.)→ Ordinary Shares (229,660 underlying)
Footnotes (4)
- [F1]The Series A Preferred Shares automatically converted into Ordinary Shares of the Issuer on a 1-to-1 basis upon closing of the initial public offering of the Issuer and had no expiration date.
- [F2]These shares are held directly by Canaan X L.P. (the "Canaan Fund"). The sole general partner of the Canaan Fund is Canaan Partners X LLC ("Canaan X", and together with the Canaan Fund, the "Canaan Entities"). Investment and voting decisions with respect to the shares held by the Canaan Fund are made by the managers of Canaan X, collectively. The Reporting Person, a manager and member of Canaan X, serves as the representative of the Canaan Entities on the Issuer's board of directors. The Reporting Person disclaims Section 16 beneficial ownership in the securities held by the Canaan Entities, except to the extent of his pecuniary interest therein, if any, in such securities by virtue of the limited liability company interests he owns in Canaan X.
- [F3]The Series B-1 Preferred Shares automatically converted into Ordinary Shares of the Issuer on a 1-to-1 basis upon closing of the initial public offering of the Issuer and had no expiration date.
- [F4]The Series B-2 Preferred Shares automatically converted into Ordinary Shares of the Issuer on a 1-to-1 basis upon closing of the initial public offering of the Issuer and had no expiration date.
Documents
Issuer
Iterum Therapeutics plc
CIK 0001659323
Entity typeother
Related Parties
1- filerCIK 0001322927
Filing Metadata
- Form type
- 4
- Filed
- May 29, 8:00 PM ET
- Accepted
- May 30, 5:26 PM ET
- Size
- 18.5 KB